Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease Journal Article

Local Library Link: Find It @ Loyola

Authors: Morales-Vidal, S.; Schneck, M. J.; Flaster, M.; Biller, J
Article Title: Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease
Abstract: Stroke is a leading cause of cardiovascular morbidity and mortality worldwide. Approximately, 795,000 strokes occur in the USA each year, 610,000 of which are first events, and 185,000 of which are recurrent events. Of all strokes, 87% are ischemic strokes. Novel anticoagulants serve as an alternative antithrombotic intervention in patients with ischemic cerebrovascular disease. This paper reviews the role of the novel anticoagulants, dabigatran, rivaroxaban and apixaban, in stroke prevention among patients with nonvalvular atrial fibrillation.
Journal Title: Expert Review of Neurotherapeutics
Volume: 12
Issue: 2
ISSN: 1744-8360
Publisher: Unknown  
Journal Place: England
Date Published: 2012
Start Page: 179
End Page: 189
Language: English
DOI/URL:

http://ovidsp.ovid.com/ovidweb.cgi?T=JS=Y=N=fulltext=medl=22288673
Notes: ID: 12356; Record Owner: From MEDLINE, a database of the U.S. National Library of Medicine.; Status: MEDLINE; [Review]; Publishing Model: Journal available in: Print Citation processed from: Internet; NLM Journal Code: 101129944; CAS Registry/EC Number/Name of Substance: 0 (Antithrombins). 0 (Benzimidazoles). 0 (Morpholines). 0 (N-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1H-benzimidazol-5-yl)carbonyl)-N-2-pyridinyl-beta-alanine). 0 (Pyrazoles). 0 (Pyridones). 0 (Thiophenes). 0 (apixaban). 0 (rivaroxaban). 107-95-9 (beta-Alanine). EC 3-4-21-6 (Factor Xa).; Entry Date: 20120622